Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Related Medications Videos on Diabetes Health TV
Popular Victoza Articles
Highly Recommended Victoza Articles
Victoza
Updated 27 weeks ago
Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
0 comments - Nov 20, 2012 -
Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
0 comments - Nov 5, 2012 -
Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk's Victoza. Following these developments, some critics said that she was a poor role model.
2 comments - Aug 28, 2012 -
Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma.
0 comments - Mar 29, 2012 -
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.
2 comments - Feb 3, 2012 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
2 comments - Dec 15, 2011 -
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.
0 comments - Oct 2, 2011 -
Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.
2 comments - Jul 11, 2011 -
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
0 comments - May 23, 2011 -
Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.
0 comments - Aug 5, 2010 -
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia